Mahboob Vaseem sold $2.4M of KMTS

Mahboob Vaseem (Chief Financial Officer) sold 79,500 shares of KESTRA MEDICAL TECHNOLOGIES, LTD. (KMTS) at an average of $30.30 ($30.04–$30.60, $2.41M total) across 3 trades over 2026-10-27 to 2026-10-29 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Mahboob Vaseem
Published Oct 29, 2026, 10:46 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 29, 2026, 10:47 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$KMTS
Neutral
medium confidence
Mentioned
$KMTS
Relevance
5/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$KMTSNeutralLow
01

Why it matters

The disclosed sale provides fresh, primary‑source information but is modest in scale, suggesting limited trading impact.

02

Market read

The filing is a primary disclosure of an insider sale, offering new data for investors but with low materiality.

03

What to watch

Potential upcoming earnings or product announcements could offset any negative sentiment from the insider sale.

Relevance 5/10Novelty 4/10Timing: after‑hours filing today

Background

SEC Form 4 filing discloses an insider transaction by KMTS's CFO under a pre‑arranged 10b5‑1 plan.

Company-level read

Ticker impact

$KMTSNeutralMedium confidence
Context

CFO Mahboob Vaseem sold 79,500 shares for $2.4M via a 10b5‑1 plan, reducing his stake to 60,609 shares.

Expected impact

likely slight pressure as the market absorbs the CFO's $2.4M share sale

Evidence & confidence

A $2.4M sale by a senior officer is material enough to be noted but not large enough to drive a significant move; the 10b5‑1 plan suggests pre‑arranged execution rather than a reaction to new information.

Market effects

Minor impact on the medical‑device sector; no broader industry catalyst.

U.S. market only; limited regional effect.

Low global relevance; isolated to KMTS shareholders.

Counterpoint

The sale could be a routine liquidity event unrelated to company fundamentals, so price may remain stable.

Key entities

  • KestrA Medical Technologies, Ltd.

    Issuer of the Form 4 filing, ticker KMTS.

  • Mahboob Vaseem

    Chief Financial Officer of KMTS, seller of the shares.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$KMTSMedAI 8/10

Kestra study shows 100% shock conversion in wearable defibrillator

Kestra Medical Technologies (KMTS) reported 100% conversion success in its ASSURE Wearable Cardioverter Defibrillator study, meeting safety and effectiveness goals. The study, involving 21,612 patients, showed a 0.0065 inappropriate-shock rate and 94% of patients with no false alarms. The company plans an algorithm update to reduce inappropriate shocks by 70%.

$KMTSHigh

Why is Kestra Medical stock gaining today?

Kestra Medical Technologies (KMTS) stock rose 0.4% to $29.50 in pre-market trading after Evercore ISI initiated coverage with an Outperform rating and $34.00 price target. The firm cited Kestra's potential in the wearable cardioverter defibrillator market, projected 30%+ annual revenue growth, and gross margin expansion to mid-70% by 2030. The move contrasts with a mixed broader market.

$KMTSHighAI 8/10

Kestra Medical Technologies Signals Profitable Growth Path

Kestra Medical Technologies (KMTS) reported Q1 revenue of $31M, up 60% YoY, with gross margin at 56.5%, up from 45.7% YoY. The company raised 2027 revenue guidance to $141M and expects profitability within a few years. Management highlighted strong growth drivers, including market expansion and automation.